Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00088673|
Recruitment Status : Unknown
Verified February 2007 by Bellus Health Inc.
Recruitment status was: Active, not recruiting
First Posted : August 3, 2004
Last Update Posted : February 28, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: 3APS||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||950 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer's Disease|
|Study Start Date :||June 2004|
- The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.
- The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088673